ORKA-001在中度至重度斑块型银屑病患者中的剂量范围研究 (EVERLAST-B)
一项关于ORKA-001在中度至重度斑块状银屑病患者中进行的多中心、随机、双盲、安慰剂对照、剂量范围探索研究
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
研究概览
详细说明
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
British Columbia
-
Surrey、British Columbia、加拿大、V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey、British Columbia、加拿大、V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton、New Brunswick、加拿大、E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax、Ontario、加拿大、L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham、Ontario、加拿大、L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough、Ontario、加拿大、K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal、Quebec、加拿大、HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec、Quebec、加拿大、G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg、Baden-Wuerrtemberg、德国、69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim、Lower Saxony、德国、48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel、Schleswig-Holstein、德国、24105
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock、Arkansas、美国、72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles、California、美国、90045
- Oruka Therapeutics Investigative Site
-
Los Angeles、California、美国、90024
- Oruka Therapeutics Investigative Site
-
San Diego、California、美国、92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami、Florida、美国、33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows、Illinois、美国、60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield、Indiana、美国、46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville、Maryland、美国、20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens、New York、美国、11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- Oruka Therapeutics Investigative Site
-
Mason、Ohio、美国、45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland、Oregon、美国、97201
- Oruka Therapeutics Investigative Site
-
Portland、Oregon、美国、97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco、Texas、美国、75033
- Oruka Therapeutics Investigative Site
-
Houston、Texas、美国、77004
- Oruka Therapeutics Investigative Site
-
Webster、Texas、美国、77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona、Barcelona、西班牙、08916
- Oruka Therapeutics Investigative Site
-
Barcelona、Barcelona、西班牙、08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid、Madrid、西班牙、28002
- Oruka Therapeutics Investigative Site
-
Madrid、Madrid、西班牙、28046
- Oruka Therapeutics Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:(Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
实验性的:(Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
实验性的:(Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
安慰剂比较:(Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
实验性的:(Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
实验性的:(Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
安慰剂比较:(Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
大体时间:Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
大体时间:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
大体时间:Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
大体时间:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
大体时间:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
大体时间:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
大体时间:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
大体时间:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
大体时间:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
大体时间:Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.